Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warnings Experts caution the move amounts to a “huge, unregulated, natural experiment”

Raja Flores says oncology is loose with staging jargon, and now “it’s confusing my patients.”

In last week’s issue of The Cancer Letter, Raja Flores wrote a guest editorial explaining how he, with his expertise in thoracic surgery, took issue with a nuance in a recent Keytruda commercial.

August 19, 2026

Clinical Roundup

Traditional prostate cancer risk factors do not predict hormone therapy benefit, UCLA-led study finds

Traditional pathological features used to classify aggressive prostate cancer—such as high-grade disease, cancer extending outside the prostate and cancer involving the seminal vesicles—after surgery do not predict who will benefit more from adding hormone therapy to postoperative radiation, according to a study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

August 14, 2026

Vol.52 No.32

Clinical Roundup

Half of prostate cancer focal therapy use falls outside current guideline-supported patient groups, study finds

As focal therapy gains popularity as a less invasive treatment option for some men with prostate cancer, a national study led by researchers at the University of Pittsburgh found that some men may be receiving treatment that is either unnecessary or not aggressive enough for their cancer.

August 14, 2026

Vol.52 No.32

Drugs & Targets

FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma

FDA granted accelerated approval to iberdomide (Zenbexus) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.

August 14, 2026

Vol.52 No.32

Drugs & Targets

FDA advisory committee to vote on GRAIL’s multi-cancer detection test, Galleri

FDA announced a forthcoming hybrid meeting of the Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee on Sept. 23 to discuss, make recommendations, and vote on information regarding the premarket approval application for the Galleri test sponsored by GRAIL, Inc.

August 14, 2026

Vol.52 No.32

Drugs & Targets

FDA approves companion diagnostic supporting patients with advanced melanoma

FDA approved Labcorp’s PGDx elio tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma with certain BRAF variants who may benefit from treatment with FDA-approved targeted therapies.

August 14, 2026

Vol.52 No.32

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warnings

Experts caution the move amounts to a “huge, unregulated, natural experiment”

YOU MAY BE INTERESTED IN

Raja Flores says oncology is loose with staging jargon, and now “it’s confusing my patients.”

Traditional prostate cancer risk factors do not predict hormone therapy benefit, UCLA-led study finds

Half of prostate cancer focal therapy use falls outside current guideline-supported patient groups, study finds

FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma

FDA advisory committee to vote on GRAIL’s multi-cancer detection test, Galleri

FDA approves companion diagnostic supporting patients with advanced melanoma

Renew today!

Subscriber content

Never miss an issue!

Login